Archemix Announces Strategic Alliance With Elan to Discover and Develop Aptamer Therapeutics
Archemix Corp. announced today a multi-year, multi-product alliance with Elan Corporation plc focused on the discovery, development, and commercialisation of first-in-class aptamer therapeutics to treat autoimmune disease. The companies will seek to develop aptamer therapeutics to IL-23, a cytokine that has emerged as a mediator in the chronic autoimmune inflammatory diseases, and additional protein targets. The collaboration combines Archemix's extensive expertise in aptamer ...
Read more : IL23
| Views :
798 | Replies :